B. Riley Wealth Advisors Inc. Has $232,000 Holdings in Repligen Co. (NASDAQ:RGEN)

B. Riley Wealth Advisors Inc. cut its stake in shares of Repligen Co. (NASDAQ:RGEN) by 11.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,288 shares of the biotechnology company’s stock after selling 162 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Repligen were worth $232,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Repligen by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 5,078,294 shares of the biotechnology company’s stock worth $913,077,000 after acquiring an additional 33,404 shares during the last quarter. Congress Asset Management Co. MA raised its position in shares of Repligen by 220.9% in the fourth quarter. Congress Asset Management Co. MA now owns 76,800 shares of the biotechnology company’s stock valued at $13,809,000 after buying an additional 52,868 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $164,000. V Square Quantitative Management LLC raised its position in shares of Repligen by 76.8% in the fourth quarter. V Square Quantitative Management LLC now owns 564 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 245 shares in the last quarter. Finally, Harbert Fund Advisors Inc. acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $764,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $126.59 on Friday. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The firm’s 50-day moving average price is $152.33 and its 200-day moving average price is $174.10. The firm has a market capitalization of $7.07 billion, a P/E ratio of 506.38, a P/E/G ratio of 4.11 and a beta of 1.04. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm had revenue of $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. During the same period in the previous year, the company posted $0.64 earnings per share. The company’s revenue for the quarter was down 17.1% on a year-over-year basis. Equities research analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Guggenheim began coverage on shares of Repligen in a report on Tuesday, June 18th. They set a “neutral” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and cut their price target for the stock from $180.00 to $155.00 in a report on Wednesday. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $193.00.

Insiders Place Their Bets

In related news, Director Martin D. Madaus bought 1,615 shares of Repligen stock in a transaction dated Friday, June 14th. The stock was purchased at an average cost of $124.94 per share, with a total value of $201,778.10. Following the transaction, the director now directly owns 4,613 shares of the company’s stock, valued at $576,348.22. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Repligen news, CEO Anthony Hunt purchased 2,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were bought at an average cost of $124.08 per share, for a total transaction of $248,160.00. Following the purchase, the chief executive officer now owns 165,177 shares of the company’s stock, valued at approximately $20,495,162.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Martin D. Madaus bought 1,615 shares of the stock in a transaction on Friday, June 14th. The stock was purchased at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the purchase, the director now directly owns 4,613 shares in the company, valued at $576,348.22. The disclosure for this purchase can be found here. 1.20% of the stock is currently owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.